Total Payments
$802.87
2024 Payments
$250.14
Companies
7
Transactions
42
Medicare Patients
1,595
Medicare Billing
$144,249
Payment Breakdown by Category
Food & Beverage$802.87 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $802.87 | 42 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $262.03 | 12 | $0 (2024) |
| Corium, LLC | $155.69 | 13 | $0 (2023) |
| Lilly USA, LLC | $103.05 | 7 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $101.32 | 1 | $0 (2022) |
| Eisai Inc. | $89.20 | 4 | $0 (2024) |
| Lundbeck LLC | $54.50 | 3 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $37.08 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $250.14 | 13 | Eisai Inc. ($89.20) |
| 2023 | $451.41 | 28 | Otsuka America Pharmaceutical, Inc. ($201.99) |
| 2022 | $101.32 | 1 | Janssen Pharmaceuticals, Inc ($101.32) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: PSYCHIATRY | ||||||
| 05/08/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.78 | General |
| Category: PSYCHIATRY | ||||||
| 05/08/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Neuroscience | ||||||
| 05/02/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Neurology | ||||||
| 05/01/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: PSYCHIATRY | ||||||
| 04/29/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: NEUROLOGY | ||||||
| 03/20/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: Neurology | ||||||
| 02/21/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Neurology | ||||||
| 02/20/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: PSYCHIATRY | ||||||
| 02/06/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: PSYCHIATRY | ||||||
| 02/01/2024 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Neuroscience | ||||||
| 01/29/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Neurology | ||||||
| 01/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.35 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: PSYCHIATRY | ||||||
| 11/09/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: PSYCHIATRY | ||||||
| 10/31/2023 | Corium, LLC | Adlarity (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 10/30/2023 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: NEUROLOGY | ||||||
| 10/17/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: PSYCHIATRY | ||||||
| 10/11/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: PSYCHIATRY | ||||||
| 10/04/2023 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Neuroscience | ||||||
| 10/04/2023 | Corium, LLC | Adlarity (Drug) | Food and Beverage | In-kind items and services | $3.19 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 09/19/2023 | Corium, LLC | Adlarity (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 09/08/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: PSYCHIATRY | ||||||
| 09/06/2023 | Corium, LLC | Adlarity (Drug) | Food and Beverage | In-kind items and services | $3.61 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 09/01/2023 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 435 | 539 | $161,681 | $49,773 |
| 2022 | 4 | 397 | 413 | $335,538 | $34,268 |
| 2021 | 5 | 354 | 371 | $291,308 | $29,935 |
| 2020 | 4 | 409 | 427 | $326,935 | $30,273 |
Total Patients
1,595
Total Services
1,750
Medicare Billing
$144,249
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 195 | 292 | $60,736 | $25,326 | 41.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 66 | 66 | $21,186 | $7,491 | 35.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 41 | 46 | $12,926 | $6,068 | 46.9% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 24 | 24 | $33,600 | $3,351 | 10.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 53 | 54 | $7,398 | $3,219 | 43.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,464 | $2,489 | 38.5% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 19 | 19 | $17,765 | $1,693 | 9.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 21 | 22 | $1,606 | $136.18 | 8.5% |
| 99285 | Emergency department visit for life threatening or functioning severity | Facility | 2022 | 163 | 165 | $231,000 | $24,008 | 10.4% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 84 | 87 | $81,345 | $8,254 | 10.1% |
| 99283 | Emergency department visit for problem of moderate severity | Facility | 2022 | 20 | 20 | $12,900 | $1,131 | 8.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 130 | 141 | $10,293 | $875.63 | 8.5% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 140 | 141 | $197,400 | $20,524 | 10.4% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 55 | 55 | $51,425 | $5,090 | 9.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 12 | 12 | $18,000 | $2,272 | 12.6% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2021 | 21 | 22 | $14,190 | $1,139 | 8.0% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 126 | 141 | $10,293 | $909.69 | 8.8% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 181 | 182 | $254,800 | $24,085 | 9.5% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 49 | 49 | $45,815 | $4,196 | 9.2% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 158 | 175 | $12,775 | $1,148 | 9.0% |
| 99283 | Emergency department visit, moderately severe problem | Facility | 2020 | 21 | 21 | $13,545 | $843.75 | 6.2% |
About Thomas Doohan
Thomas Doohan is a Emergency Medicine healthcare provider based in Waxhaw, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700811858.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Thomas Doohan has received a total of $802.87 in payments from pharmaceutical and medical device companies, with $250.14 received in 2024. These payments were reported across 42 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($802.87).
As a Medicare-enrolled provider, Doohan has provided services to 1,595 Medicare beneficiaries, totaling 1,750 services with total Medicare billing of $144,249. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Other Specialties General Practice
- Location Waxhaw, NC
- Active Since 07/11/2006
- Last Updated 03/02/2021
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1700811858
Products in Payments
- REXULTI (Drug) $268.88
- Adlarity (Drug) $155.69
- XARELTO (Drug) $101.32
- AMYVID (Drug) $89.49
- Leqembi (Drug) $89.20
- NUEDEXTA (Drug) $84.73
- EMGALITY (Drug) $13.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.